title: Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV.
abstract: The aims of this study were to select the patients with a potential for progression to hepatic failure due to lamivudine-resistant HBV and to standardize the treatment for patients with lamivudine-resistant HBV. Patients (n = 47) with reactivated hepatitis due to lamivudine-resistant HBV were classified into two groups, with and without potential for progression to hepatic failure, according to the criteria using the data of serum bilirubin level and prothrombin activity after the reactivated hepatitis. Multivariate analysis showed that prothrombin activity at the initiation of lamivudine therapy was related to the deterioration of the liver function after the emergence of lamivudine-resistant HBV (P = 0.0025, 95%CI 0.8269-0.9601). We assume that earlier additional or substitutive treatment with other antiviral agent, such as adefovir dipivoxil, should be recommended when the lamivudine-resistant HBV is detected in patients with the history of decompensated liver disease before the administration of lamivudine, even when hepatitis has not been reactivated yet.
authors.affiliation: Kurume University School of Medicine, Kurume, 830-0011, Japan. ray@med.kurume-u.ac.jp
authors.forename: Reiichiro
authors.initials: R
authors.lastname: Kuwahara
authors.forename: Ryukichi
authors.initials: R
authors.lastname: Kumashiro
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Ide
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Koga
authors.forename: Teruko
authors.initials: T
authors.lastname: Hino
authors.forename: Akiko
authors.initials: A
authors.lastname: Hisamochi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tanaka
authors.forename: Kei
authors.initials: K
authors.lastname: Ogata
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Koga
authors.forename: Yukari
authors.initials: Y
authors.lastname: Takao
authors.forename: Michio
authors.initials: M
authors.lastname: Sata
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D018450:Disease Progression; D024882:Drug Resistance, Viral; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology / Q000627:therapeutic use*; D017093:Liver Failure / Q000097:blood / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis; D011517:Prothrombin Time; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D019259:Lamivudine; D000225:Adenine; D001663:Bilirubin; C106812:adefovir dipivoxil